AR083533A1 - Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe - Google Patents
Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripeInfo
- Publication number
- AR083533A1 AR083533A1 ARP110103916A ARP110103916A AR083533A1 AR 083533 A1 AR083533 A1 AR 083533A1 AR P110103916 A ARP110103916 A AR P110103916A AR P110103916 A ARP110103916 A AR P110103916A AR 083533 A1 AR083533 A1 AR 083533A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- treatment
- nucleic acid
- amino acid
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se provee además una molécula de ácido nucleico que codifica la proteína H5 del virus de la gripe, vector que comprende dicho ácido nucleico.Reivindicación 1: Proteína H5 del virus de la gripe, caracterizada porque la proteína H5 tiene (a) los aminoácidos 113D, 126H, 145(-), 156R, 160F, 167T, y 181N, en los que la modificación 145(-) significa que la posición del aminoácido 145 de H5 está delecionada, o (b) los aminoácidos 87P, 145L, 172T, 201E, 206I, 208K, 254T, 341G y 421K, o (c) los aminoácidos 145L, 172T, y 254V, y en los que la numeración de las posiciones de aminoácidos de la proteína H5 se refiere a la posición de aminoácido dada como ejemplo en la SEQ ID Nº 1, o (d) donde la proteína H5 comprende o consiste en una secuencia de aminoácidos que tiene al menos el 95%, preferiblemente al menos 96%, más preferiblemente al menos 97%, aún más preferiblemente al menos 98%, todavía más preferiblemente al menos 99%, o en particular preferiblemente el 100% de homología con una cualquiera de las secuencias indicadas en las SEQ ID Nº 2 a 40. Reivindicación 13: Una vacuna caracterizada porque comprende: a) la proteína H5 según una cualquiera de las reivindicaciones 1 a 10, la molécula de ácido nucleico según la reivindicación 11 o el vector según la reivindicación 12, y b) un vehículo y/o excipiente farmacéuticamente aceptable. Reivindicación 24: Un método para el tratamiento o la profilaxis de infecciones del virus de la gripe, caracterizado porque comprende la administración de una cantidad terapéuticamente eficaz de la proteína H5 según las reivindicaciones 1 a 10, a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz del ácido nucleico H5 según la reivindicación 11 o del vector según la reivindicación 12 a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz de la vacuna según la reivindicación 13 ó 14, a un sujeto que necesite dicho tratamiento, y donde en uno cualquiera de dichos métodos, la infección de gripe está causada en particular por un virus de la gripe aviar, porcina o humana o por cualquiera de sus combinaciones o híbridos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188576 | 2010-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083533A1 true AR083533A1 (es) | 2013-03-06 |
Family
ID=43734836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103916A AR083533A1 (es) | 2010-10-22 | 2011-10-21 | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2630155B1 (es) |
| CN (1) | CN103429611A (es) |
| AR (1) | AR083533A1 (es) |
| ES (1) | ES2798326T3 (es) |
| WO (1) | WO2012054907A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104780936A (zh) * | 2012-11-16 | 2015-07-15 | 米迪缪尼有限公司 | 猪流感血球凝集素与神经氨酸酶变体 |
| AU2014237485A1 (en) * | 2013-03-15 | 2015-10-22 | Novavax, Inc. | Enhanced expression of picornavirus proteins |
| GB2547494B (en) * | 2013-12-23 | 2020-05-20 | Temasek Life Sciences Laboratory Ltd | Monovalent H5 vaccine |
| GB201507723D0 (en) * | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| CA3131096A1 (en) | 2019-04-05 | 2020-10-08 | Chi-Huey Wong | Sialidase-resistant saccharide and method of making and using the same |
| EP4146241A4 (en) | 2020-05-08 | 2024-06-05 | Academia Sinica | CHIMERIC INFLUENZA VACCINES |
| EP4164687A4 (en) | 2021-04-12 | 2024-08-14 | Academia Sinica | IMPROVED CORONAVIRUS VACCINE |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| EP4412644A1 (en) * | 2021-10-06 | 2024-08-14 | DIOSynVax Ltd | Influenza vaccines |
| CN121240887A (zh) | 2023-04-08 | 2025-12-30 | 磐石医药生技股份有限公司 | 通过聚合物囊泡进行靶向递送的方法和组合物 |
| WO2024215614A2 (en) | 2023-04-08 | 2024-10-17 | Rock Biomedical Inc. | Methods and compositions for dendritic cell targeting nano-delivery |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1026253B2 (en) | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| US5690938A (en) | 1989-07-07 | 1997-11-25 | Oravax, Inc. | Oral immunization with multiple particulate antigen delivery system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| BR9106374A (pt) | 1990-04-24 | 1993-03-30 | Univ Newcastle Res Ass | Vacina oral e processo de extrair uma imunoresponsta em um mamifero |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| DE69229390T2 (de) | 1991-08-26 | 1999-11-11 | Immuno Ag, Wien | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
| US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5807722A (en) | 1992-10-30 | 1998-09-15 | Bioengineering Resources, Inc. | Biological production of acetic acid from waste gases with Clostridium ljungdahlii |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| EP0740704A1 (en) | 1994-01-27 | 1996-11-06 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
| DE69534289T2 (de) | 1994-04-29 | 2006-04-27 | Baxter Healthcare S.A. | Rekombinante Pockenviren mit fremden Polynukleotiden in wichtigen Regionen |
| AU711702B2 (en) | 1995-03-23 | 1999-10-21 | Cambridge University Technical Services Limited | Vectors for gene delivery |
| EP0979101B1 (en) | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| NZ521840A (en) | 2000-04-28 | 2004-11-26 | St | Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA |
| WO2002003872A2 (en) | 2000-07-11 | 2002-01-17 | Johns Hopkins University | Application of photochemotherapy for the treatment of cardiac arrhythmias |
| EP2029167A4 (en) * | 2006-06-16 | 2010-06-16 | Dow Agrosciences Llc | NEW DNA SEQUENCES, VECTORS AND PROTEINS OF BIRD FLUID HEMOGGLUTININE |
| JP6029586B2 (ja) * | 2010-10-04 | 2016-11-24 | マサチューセッツ インスティテュート オブ テクノロジー | 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法 |
-
2011
- 2011-10-21 AR ARP110103916A patent/AR083533A1/es unknown
- 2011-10-22 EP EP11778762.2A patent/EP2630155B1/en active Active
- 2011-10-22 CN CN2011800617190A patent/CN103429611A/zh active Pending
- 2011-10-22 WO PCT/US2011/057406 patent/WO2012054907A2/en not_active Ceased
- 2011-10-22 ES ES11778762T patent/ES2798326T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103429611A (zh) | 2013-12-04 |
| WO2012054907A2 (en) | 2012-04-26 |
| EP2630155A2 (en) | 2013-08-28 |
| ES2798326T3 (es) | 2020-12-10 |
| WO2012054907A3 (en) | 2012-06-21 |
| EP2630155B1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083533A1 (es) | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| PE20180571A1 (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| AR105822A1 (es) | Análogos de insulina | |
| BRPI0923346A2 (pt) | Proteinas em super-helice antiparalela de cadeia simples | |
| MX2014006396A (es) | Vacunas contra el virus de la influenza y sus usos. | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| AR088737A1 (es) | Familia de toxinas inhibidoras de insectos activa contra insectos hemipteros y/o lepidopteros | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
| AR090439A1 (es) | Lipopeptidos antimicrobianos cortos | |
| MX2019003116A (es) | Nueva vacuna contra la gripe porcina. | |
| AR083839A1 (es) | Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos | |
| MX350306B (es) | Vacuna y metodos para reducir una infeccion por campylobacter. | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| PE20230343A1 (es) | Peptidos que estimulan respuestas inmunitarias antitumorales | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |